250 related articles for article (PubMed ID: 32480315)
1. Towards a more precise therapy in cancer: Exploring epigenetic complexity.
Cossío FP; Esteller M; Berdasco M
Curr Opin Chem Biol; 2020 Aug; 57():41-49. PubMed ID: 32480315
[TBL] [Abstract][Full Text] [Related]
2. Epidrugs: targeting epigenetic marks in cancer treatment.
Miranda Furtado CL; Dos Santos Luciano MC; Silva Santos RD; Furtado GP; Moraes MO; Pessoa C
Epigenetics; 2019 Dec; 14(12):1164-1176. PubMed ID: 31282279
[TBL] [Abstract][Full Text] [Related]
3. Cancer epigenetics: Moving forward.
Nebbioso A; Tambaro FP; Dell'Aversana C; Altucci L
PLoS Genet; 2018 Jun; 14(6):e1007362. PubMed ID: 29879107
[TBL] [Abstract][Full Text] [Related]
4. Leveraging epigenetics to enhance the efficacy of immunotherapy.
Licht JD; Bennett RL
Clin Epigenetics; 2021 May; 13(1):115. PubMed ID: 34001289
[TBL] [Abstract][Full Text] [Related]
5. The Role of Epigenetic Modifications in Human Cancers and the Use of Natural Compounds as Epidrugs: Mechanistic Pathways and Pharmacodynamic Actions.
Bouyahya A; Mechchate H; Oumeslakht L; Zeouk I; Aboulaghras S; Balahbib A; Zengin G; Kamal MA; Gallo M; Montesano D; El Omari N
Biomolecules; 2022 Feb; 12(3):. PubMed ID: 35327559
[TBL] [Abstract][Full Text] [Related]
6. The Contribution of Epigenetics to Cancer Immunotherapy.
Villanueva L; Álvarez-Errico D; Esteller M
Trends Immunol; 2020 Aug; 41(8):676-691. PubMed ID: 32622854
[TBL] [Abstract][Full Text] [Related]
7. Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise.
Morel D; Jeffery D; Aspeslagh S; Almouzni G; Postel-Vinay S
Nat Rev Clin Oncol; 2020 Feb; 17(2):91-107. PubMed ID: 31570827
[TBL] [Abstract][Full Text] [Related]
8. Epigenetically Active Drugs Inhibiting DNA Methylation and Histone Deacetylation.
Chistiakov DA; Myasoedova VA; Orekhov AN; Bobryshev YV
Curr Pharm Des; 2017; 23(8):1167-1174. PubMed ID: 27774908
[TBL] [Abstract][Full Text] [Related]
9. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
[TBL] [Abstract][Full Text] [Related]
10. Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Stegmaier K; Bourdeaut F; Reaman G; Heenen D; Meyers ML; Armstrong SA; Brown P; De Carvalho D; Jabado N; Marshall L; Rivera M; Smith M; Adamson PC; Barone A; Baumann C; Blackman S; Buenger V; Donoghue M; Duncan AD; Fox E; Gadbaw B; Hattersley M; Ho P; Jacobs I; Kelly MJ; Kieran M; Lesa G; Ligas F; Ludwinski D; McDonough J; Nikolova Z; Norga K; Senderowicz A; Taube T; Weiner S; Karres D; Vassal G
Eur J Cancer; 2020 Nov; 139():135-148. PubMed ID: 32992153
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic reprogramming and potential application of epigenetic-modifying drugs in acquired chemotherapeutic resistance.
Ponnusamy L; Mahalingaiah PKS; Singh KP
Adv Clin Chem; 2020; 94():219-259. PubMed ID: 31952572
[TBL] [Abstract][Full Text] [Related]
12. [Targeted epigenetic therapy of cancer. Achievements and perspectives].
Valdespino-Gómez VM; Valdespino-Castillo VE
Cir Cir; 2012; 80(5):470-80. PubMed ID: 23351455
[TBL] [Abstract][Full Text] [Related]
13. Advances in epigenetic therapeutics with focus on solid tumors.
Jin N; George TL; Otterson GA; Verschraegen C; Wen H; Carbone D; Herman J; Bertino EM; He K
Clin Epigenetics; 2021 Apr; 13(1):83. PubMed ID: 33879235
[TBL] [Abstract][Full Text] [Related]
14. Targeting the epigenetic regulation of antitumour immunity.
Hogg SJ; Beavis PA; Dawson MA; Johnstone RW
Nat Rev Drug Discov; 2020 Nov; 19(11):776-800. PubMed ID: 32929243
[TBL] [Abstract][Full Text] [Related]
15. Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism.
Morel D; Almouzni G; Soria JC; Postel-Vinay S
Ann Oncol; 2017 Feb; 28(2):254-269. PubMed ID: 28426098
[TBL] [Abstract][Full Text] [Related]
16. Modulating epigenetic modifications for cancer therapy (Review).
Castro-Muñoz LJ; Ulloa EV; Sahlgren C; Lizano M; De La Cruz-Hernández E; Contreras-Paredes A
Oncol Rep; 2023 Mar; 49(3):. PubMed ID: 36799181
[TBL] [Abstract][Full Text] [Related]
17. Targeting epigenetics for cancer therapy.
Park JW; Han JW
Arch Pharm Res; 2019 Feb; 42(2):159-170. PubMed ID: 30806885
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic therapy in immune-oncology.
Jones PA; Ohtani H; Chakravarthy A; De Carvalho DD
Nat Rev Cancer; 2019 Mar; 19(3):151-161. PubMed ID: 30723290
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
Teodoridis JM; Strathdee G; Brown R
Drug Resist Updat; 2004; 7(4-5):267-78. PubMed ID: 15533764
[TBL] [Abstract][Full Text] [Related]
20. The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy.
Loo Yau H; Ettayebi I; De Carvalho DD
Trends Cell Biol; 2019 Jan; 29(1):31-43. PubMed ID: 30153961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
